Gene-Sequencing Company Illumina to Sell Cancer Test Developer

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The New York Times - Business:

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.

This post first appeared in The New York Times - Business. Read the original article.